Welcome to our dedicated page for United States Antimony SEC filings (Ticker: UAMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The United States Antimony Corporation (UAMY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. UAMY’s common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on the NYSE American and NYSE Texas, so investors can review a range of filings, including Form 8-K current reports that detail material events and corporate developments.
Recent Form 8-K filings for United States Antimony cover topics such as entry into material definitive agreements, including a five-year supply agreement with a U.S. industrial fabric manufacturer for antimony trioxide, and capital markets transactions under shelf registration statements and sales agreements. Other 8-Ks report on operational updates, preliminary revenue guidance, and proposals related to potential acquisitions, as well as the appointment of new independent directors and the formation of board committees.
Filings also disclose information about conference calls and press releases reporting financial and operational results for periods such as the third quarter and nine months ended September 30, 2025. These documents outline revenues, gross profit, operating expenses, net loss, and balance sheet data, along with narrative discussion of antimony and zeolite sales and capital expenditures for smelter expansion and mineral rights purchases.
On this page, Stock Titan pairs real-time updates from the SEC’s EDGAR system with AI-powered summaries that help explain the significance of each filing. Investors can quickly scan Form 8-K disclosures for key points on contracts, financing, governance changes, and operational guidance, and then dive into the full text when more detail is needed. For those tracking UAMY’s role in antimony, zeolite, and critical minerals, these filings provide an official record of the company’s regulatory and financial reporting.
UNITED STATES ANTIMONY CORP director Blaise A. Aguirre reported multiple dispositions of common stock back to the company. On March 31, 2026, he disposed of several blocks totaling 27,000 shares at prices between $8.20 and $8.26 per share, each coded as a “Disposition to issuer” (D). After these transactions, he directly held 845,754 shares of United States Antimony common stock.
UNITED STATES ANTIMONY CORP director and executive officer Lloyd Bardswich reported two dispositions of common stock back to the issuer. On March 26, 2026, he disposed of 46,674 shares at $9.34 per share, and on March 27, 2026, he disposed of 36,181 shares at $9.05 per share.
Across both transactions, a total of 82,855 common shares were returned to the company. Following these issuer dispositions, Bardswich directly holds 937,355 shares of UNITED STATES ANTIMONY CORP common stock, indicating he retains a substantial equity position after the reported activity.
UNITED STATES ANTIMONY CORP director Blaise A. Aguirre reported returning shares of common stock to the company. On March 24, 2026, he disposed of 20,000 shares at $9.16 per share, a transaction classified as a "Disposition to issuer".
On March 27, 2026, he reported two additional dispositions to the issuer of 6,339 shares at $8.78 per share and 5,373 shares at $8.77 per share. After these transactions, he directly held 872,754 shares of common stock, indicating that only a small portion of his overall position was returned to the company.
UNITED STATES ANTIMONY CORP granted equity awards to Chairman & CEO Gary C. Evans as part of compensation. He received a time-based restricted stock unit (RSU) award covering 304,524 shares of Common Stock under the Amended & Restated 2023 Equity Incentive Plan. One-third, or 101,508 shares, vest on January 15, 2026, with additional one-third portions vesting on January 15, 2027 and January 18, 2028, subject to continued service. He also received a stock option for 308,133 shares of Common Stock with a conversion or exercise price of $8.29 per share, which can vest upon meeting specified performance measures at any time during its 10-year term, also contingent on continued service. These are grant/award acquisitions, not open-market purchases or sales.
United States Antimony Corp granted equity awards to John C. Gustavsen, its President, Antimony Division. He received a restricted stock unit award covering 50,754 shares of Common Stock, vesting in three equal installments on January 15, 2026, January 15, 2027, and January 18, 2028, subject to continued service. He was also granted a stock option over 61.627 shares of Common Stock at an exercise price of $8.2900 per share, which vests upon achieving specified performance measures at any time during its 10-year term, also conditioned on continued service. These are compensation-related grants, not open-market purchases or sales.
United States Antimony Corp Schedule 13G/A: The Vanguard Group reports 0 shares beneficially owned, representing 0% of the common stock. The amendment explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538, causing certain Vanguard subsidiaries or business divisions to report separately. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
UNITED STATES ANTIMONY CORP reported an insider transaction by its SVP and Chief Financial Officer, Richard R. Isaak. He disposed of a total of 83,334 shares of common stock back to the company in two issuer-related transactions, not open-market sales.
On March 25, he returned 30,000 shares at $10.00 per share, and on March 26, he returned 53,334 shares at $9.00 per share. Following these transactions, he directly holds 354,886 shares of common stock.
United States Antimony Corp Chairman and CEO Gary C. Evans reported four issuer dispositions of Common Stock on March 25, 2026, totaling 400,000 shares at prices between 9.76 and 9.88 per share. After these transactions, he directly owns 2,231,951 shares.
US Antimony (UAMY) submitted a Form 144 reporting proposed sales of common stock. The filing lists two restricted common share entries of 66,667 shares dated 03/03/2025 and 05/15/2024 and reports 30,000 shares sold during the past three months on 03/25/2026.
The notice names Merrill (address shown) as the broker and indicates the securities trade on the NYSE. The filing is a routine notification of proposed or recent dispositions of restricted common stock.
UAMY proposed multiple open-market sales of Common Stock via Form 144, listing sale blocks on December 6–9 and December 12–13, 2022. The excerpt shows individual proposed sale amounts of 40,000, 251,281, 51,653 and 57,066 shares on those dates.